MD Communications Group
  • Home
  • Services
  • Areas of Expertise
  • Qualifications
  • Clients
  • Contact

        Gastroenterology

                     At a glance...
  • Crohn's disease/ulcerative colitis, irritable bowel syndrome (IBS), dyspepsia, diarrhea, postoperative ileus, opioid bowel dysfunction, gastrointestinal stromal tumors, gastroesophageal bleeding 
  • Anti-TNF agents, 5-HT4 receptor antagonists, opioid receptor antagonists, octreotide, assay for antibodies to anti-TNF agent

Publications


Experimental studies on potential therapeutic strategies in irritable bowel syndrome  (book chapter)

“A 32-year-old woman with chronic abdominal pain” Evidence-based discussion of diagnosis, evaluation, and treatment of functional dyspepsia (Clinical Crossroads article in JAMA)

“Abdominal pain, bloating, and altered bowel habits across phases of the menstrual cycle in women with IBS: are serotonergic mechanisms involved?”  (review)

Formulary dossier for Zelnorm (indicated for IBS and chronic constipation) (AMCP dossier--clinical and economic sections)

“A review of the potential role of methylnaltrexone in opioid bowel dysfunction” (review)

“Postoperative ileus: progress toward effective management”  (review)

“ADL 8-2698 reverses morphine inhibition of gastrointestinal transit: phase 1 randomized, double-blind, placebo-controlled study”  (clinical trial)

“Hepatic safety of ADL 8-2698, a selective peripheral opioid antagonist: an ascending-dose safety study in humans” (clinical trial)

“Update on the risk-benefit profile of infliximab in the treatment of Crohn’s disease”  (meeting report)

Monograph for a novel assay for anti-human antibodies to anti-TNF agents

Back to Areas of Expertise

              
phone/fax: (760) 448-6668 | email:info@mdcommgroup.com